Allogene Therapeutics Inc (ALLO) Stock Price, Quote & News

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 2700

Website: allogene.com

Address:

210 East Grand Avenue, South San Francisco, United States

Holy_Xerxes Jun. 21 at 8:23 AM

$ALLO this company will be a threat to my AUTL in 5 to 6 years. So therefore you are my enemy.

0 · Reply

tradersunion353 Jun. 20 at 8:57 PM

$ALLO How is that adding and loading working ?? 😂😂😂

0 · Reply

tradersunion353 Jun. 20 at 2:06 PM

$ALLO I want to bring down my avg to 70 cents. Heading to 50 cents 🎉🎉🎉 Guaranteed bump to $1 to $1.50

0 · Reply

tradersunion353 Jun. 19 at 10:51 PM

$ALLO Heading to 50 cents Huge insider selling at 1 dollar levels Something is going on Buy at 50 cents and sell on bump for 1 dollar

0 · Reply

tradersunion353 Jun. 18 at 4:20 PM

$ALLO 50 cents coming soon . Huge insider selling going on 🤕

0 · Reply

Lisan_AlGaib Jun. 18 at 1:49 PM

$ALLO Thank you to who ever is selling. I will keep loading.

0 · Reply

tradersunion353 Jun. 18 at 1:33 PM

$ALLO These are same paid pumpers from yahoo boards and some here who restlessly pumps this stock irrespective of heavy insider selling Ignore these pumpers. This pos stock is heading to 50 cents Buy

0 · Reply

tradersunion353 Jun. 18 at 3:47 AM

$ALLO Crazy insider selling 😱 Next stop 50 cents

0 · Reply

Unburdened Jun. 17 at 3:13 PM

$ALLO What a DS stock this is. Can't even get a bump after the Eli Lilly acquisition today.

0 · Reply

tradersunion353 Jun. 16 at 12:35 AM

$ALLO Huge insider selling at these levels 😱 Dont be in rush to buy now.. buy at 50-60 cents

0 · Reply

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

May 29, 2025, 3:37 PM EDT - 23 days ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 28, 2025, 9:43 AM EDT - 24 days ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 23, 2025, 8:30 AM EDT - 4 weeks ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 22, 2025, 5:17 PM EDT - 4 weeks ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 13, 2025, 10:47 PM EDT - 5 weeks ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 5 weeks ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:30 AM EDT - 6 weeks ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Apr 23, 2025, 10:12 AM EDT - 2 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 7, 2025, 8:30 AM EDT - 2 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Mar 13, 2025, 11:56 PM EDT - 3 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 3 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 3 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 4 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 4 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 4 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 4 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

$Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology$

Feb 13, 2025, 4:30 PM EST - 4 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 5 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 6 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 6 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 7 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 7 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 8 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 8 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 8 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 8 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 8 months ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 9 months ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 9 months ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 10 months ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 11 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 11 months ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 8:30 AM EDT - 11 months ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 13, 2024, 7:31 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:47 PM EDT - 1 year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:01 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 6, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

Apr 4, 2024, 11:30 AM EDT - 1 year ago

Showcasing Seeking Alpha's March 2024 New Analysts

APD AXP CPS CPT DG DK EPR

Mar 14, 2024, 8:49 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Mar 5, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Feb 28, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Holy_Xerxes Jun. 21 at 8:23 AM

$ALLO this company will be a threat to my AUTL in 5 to 6 years. So therefore you are my enemy.

0 · Reply

tradersunion353 Jun. 20 at 8:57 PM

$ALLO How is that adding and loading working ?? 😂😂😂

0 · Reply

tradersunion353 Jun. 20 at 2:06 PM

$ALLO I want to bring down my avg to 70 cents. Heading to 50 cents 🎉🎉🎉 Guaranteed bump to $1 to $1.50

0 · Reply

tradersunion353 Jun. 19 at 10:51 PM

$ALLO Heading to 50 cents Huge insider selling at 1 dollar levels Something is going on Buy at 50 cents and sell on bump for 1 dollar

0 · Reply

tradersunion353 Jun. 18 at 4:20 PM

$ALLO 50 cents coming soon . Huge insider selling going on 🤕

0 · Reply

Lisan_AlGaib Jun. 18 at 1:49 PM

$ALLO Thank you to who ever is selling. I will keep loading.

0 · Reply

tradersunion353 Jun. 18 at 1:33 PM

$ALLO These are same paid pumpers from yahoo boards and some here who restlessly pumps this stock irrespective of heavy insider selling Ignore these pumpers. This pos stock is heading to 50 cents Buy

0 · Reply

tradersunion353 Jun. 18 at 3:47 AM

$ALLO Crazy insider selling 😱 Next stop 50 cents

0 · Reply

Unburdened Jun. 17 at 3:13 PM

$ALLO What a DS stock this is. Can't even get a bump after the Eli Lilly acquisition today.

0 · Reply

tradersunion353 Jun. 16 at 12:35 AM

$ALLO Huge insider selling at these levels 😱 Dont be in rush to buy now.. buy at 50-60 cents

0 · Reply

tradersunion353 Jun. 13 at 6:35 PM

$ALLO Unbelievable amount of insider selling 😱 This is dropping 50-60 cents

0 · Reply

tradersunion353 Jun. 13 at 6:34 PM

$ALLO Buy at 50-60 cents Patience is the key here Guaranteed 50-60 cents in coming weeks

0 · Reply

Lisan_AlGaib Jun. 12 at 1:46 PM

$ALLO

0 · Reply

Southshd Jun. 11 at 2:51 PM

$ALLO Holding up well today on a day when most bio stocks are down!

0 · Reply

BioBuddha Jun. 10 at 2:33 PM

$ALLO in a few years this could be in triple digits. Is there risk that it could go bk or dilute substantially ? of course there is. But there are decent odds it hits triple digits in 3-5 year

1 · Reply

Winning_calls Jun. 10 at 2:22 PM

$ALLO u can do better!!

0 · Reply

tr1llA Jun. 9 at 4:15 PM

$ALLO how come on StockAnalysis and other finance resources they show the firm revenue exploding in 2027? Is there a patent I’m not aware of? Any helpful links appreciated.

1 · Reply

Winning_calls Jun. 9 at 3:36 AM

$ALLO pick me up @ $1.43

0 · Reply

longrigger52 Jun. 6 at 11:35 PM

$ALLO im riding to 50+

1 · Reply

BioBuddha Jun. 6 at 6:44 PM

$ALLO I do not know the product the market the science behind the product. All I know is that the founder is incredible. That’s my personal thesis. Not asking others to invest. Just stating my view. That’s all.

1 · Reply

Elistyle Jun. 6 at 4:02 PM

$ALLO

0 · Reply

Mr_JokeR Jun. 6 at 3:32 PM

$ALLO this should be in the 3-4s range at minimum.

0 · Reply

Market Cap	269.04M
Revenue (ttm)	20,000.00
Net Income (ttm)	-257.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,287,950.01%
Debt to Equity Ratio	0.00

Volume	3,630,500
Avg Vol	3,121,168
Day's Range	N/A - N/A
Shares Out	218.73M
Stochastic %K	7%
Beta	0.31
Analysts	Strong Sell
Price Target	$8.15